Get the Stockscreener App
1.58
2.47%
-0.04
After Hours:
1.51
-0.07
-4.43%
Femasys Inc Stock (FEMY) Latest News
Femasys announces publication of ‘positive’ results from FemBloc trials - TipRanks
Femasys Announces Peer-Reviewed Publication of Positive - GlobeNewswire
Could This Non-Surgical Birth Control Method Replace Traditional Sterilization? Clinical Trials Say Yes - StockTitan
Head to Head Survey: Femasys (NASDAQ:FEMY) & Accuray (NASDAQ:ARAY) - Defense World
Is Femasys (NASDAQ:FEMY) Using Debt In A Risky Way? - Simply Wall St
Femasys gains UK approval for women's health products - MSN
FY2024 Earnings Estimate for Femasys Issued By HC Wainwright - Defense World
What is HC Wainwright’s Estimate for Femasys Q1 Earnings? - Defense World
Femasys gains UK approval for women’s health products By Investing.com - Investing.com Nigeria
Femasys Announces UK Regulatory Approvals for FemaSeed® for - GlobeNewswire
Femasys (NASDAQ:FEMY) Given “Buy” Rating at HC Wainwright - Defense World
Femasys gains UK approval for women's health products By Investing.com - Investing.com Australia
Major Win for Infertility Treatment: Femasys (FEMY) Unlocks UK Market with Triple Product Approval - StockTitan
Head-To-Head Survey: Sonoma Pharmaceuticals (NASDAQ:SNOA) vs. Femasys (NASDAQ:FEMY) - Defense World
Femasys gains approvals for infertility and diagnostic products in Israel - MSN
Pap Test Market: Current Analysis and Forecast (2022-2028) - UnivDatos Market Insights
Femasys Announces Israeli Regulatory Approvals for - GlobeNewswire
Major Win for Women's Health: Femasys Triple-Product Approval Opens New Market - StockTitan
Femasys announces notices of intention to grant for two new European patent applications - MSN
Femasys Announces Notices of Intention to Grant for Two New - GlobeNewswire
Game-Changing Birth Control Tech: Femasys Locks Down Crucial EU Patents for Non-Surgical Alternative - StockTitan
Femasys gets notice of allowance for new U.S. patent application covering use of Femaseed - MSN
Femasys Inc. Announces Notice of Allowance for New U.S. Patent Application Covering Use of FemaSeed® for Female Infertility Treatment - Marketscreener.com
Femasys Announces Notice of Allowance for New U.S. Patent - GlobeNewswire
Femasys Secures Patent Protection for FemaSeed Fertility Treatment Through 2044 - StockTitan
Femasys Inc. (NASDAQ:FEMY) Stock Position Raised by Geode Capital Management LLC - Defense World
Femasys (NASDAQ:FEMY) Stock Price Down 2.8% – What’s Next? - Defense World
HPV Testing & Pap Test Market 2025-2032: Scope, Trend, Expansion Strategies with SWOT Analysis - WICZ
PharmaCyte Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2024 - Marketscreener.com
Femasys (NASDAQ:FEMY) Earns “Buy” Rating from HC Wainwright - Defense World
Femasys shares hold price target with buy rating on HRC Fertility deal - Investing.com Nigeria
Intratubal Insemination Device Shown Effective, Safe - Streetwise Reports
Femasys Announces Partnership with HRC Fertility, Esteemed - GlobeNewswire
Femasys Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
The Latest Analyst Ratings For Femasys - Benzinga
Femasys Announces Peer-Reviewed Publication of Positive Data from Prospective, Multicenter Pivotal Trial of FemaSeed® Infertility Treatment - Yahoo Canada Finance
Femasys' FemaSeed Trial Shows Double Pregnancy Success vs Traditional IUI Treatment - StockTitan
Femasys price target lowered to $8 from $10 at Chardan - MSN
Femasys Third Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
Femasys Inc. (FEMY) Quarterly 10-Q Report - Quartzy
Femasys earnings missed by $0.04, revenue fell short of estimates - Investing.com South Africa
Femasys Inc. (FEMY) Reports Q3 Loss, Tops Revenue Estimates - MSN
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides Corporate Update - The Manila Times
Femasys Announces Financial Results for Quarter Ended September 30, 2024, and Provides - The Bakersfield Californian
Femasys Sales Surge 127% as Boston IVF Partnership, FDA Clearance Fuel Growth | FEMY Stock News - StockTitan
Femasys to Exhibit at the Annual AAGL 2024 Global Conference - GlobeNewswire
0.52%
2.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):